UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Intrapatient functional clonality deconvoluted by coupling intracellular flow cytometry and next-generation sequencing in human leukemia

Leukemia, 2018-02, Vol.32 (2), p.532-538

2018

Volltextzugriff (PDF)

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes

Annals of oncology, 2016-01, Vol.27 (1), p.62-68

2016

Volltextzugriff (PDF)

Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia

Haematologica (Roma), 2016-08, Vol.101 (8), p.e320-e323

2016

Volltextzugriff (PDF)

An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies

Blood cancer journal (New York), 2015-07, Vol.5 (7), p.e333-e333

2015

Volltextzugriff (PDF)

P778: LONG‐TERM UTILIZATION AND BENEFIT OF LUSPATERCEPT IN PATIENTS (PTS) WITH LOWER‐RISK MYELODYSPLASTIC SYNDROMES (LR‐MDS) FROM THE MEDALIST TRIAL

HemaSphere, 2022-06, Vol.6, p.673-674

2022

Volltextzugriff (PDF)

P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE‐2 OR HIGH‐RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR

HemaSphere, 2022-06, Vol.6 (Suppl), p.938-939

2022

Volltextzugriff (PDF)

Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes

Leukemia, 2013-10, Vol.27 (10), p.2112

2013

Volltextzugriff (PDF)

An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms

Haematologica (Roma), 2015-09, Vol.100 (9), p.1117-1130

2015

Volltextzugriff (PDF)

Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes

Leukemia, 2013-07, Vol.27 (7), p.1504-1510

2013

Volltextzugriff (PDF)

The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure

Haematologica (Roma), 2016-06, Vol.101 (6), p.e224-e227

2016

Volltextzugriff (PDF)

Timing of allo-HCT in CMML

Blood, 2022-09, Vol.140 (12), p.1452-1452

2022

Volltextzugriff (PDF)

A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction

Haematologica (Roma), 2014-07, Vol.99 (7), p.1176-1183

2014

Volltextzugriff (PDF)

Outcome of Diffuse Large B-Cell Lymphoma in the United States Has Improved Over Time but Racial Disparities Remain: Review of SEER Data

Clinical lymphoma, myeloma and leukemia, 2011-06, Vol.11 (3), p.257-260

2011

Volltextzugriff (PDF)

Erratum: Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes

Leukemia, 2013-10, Vol.27 (10), p.2112-2112

2013

Volltextzugriff (PDF)

Between a Rux and a Hard Place: Investigating Causes of Ruxolitinib Discontinuation, Salvage Treatment and Outcome in Myelofibrosis

Blood, 2017, Vol.130, p.4186-4186

2017

Volltextzugriff (PDF)

The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval

Clinical lymphoma, myeloma and leukemia, 2017-12, Vol.17 (12), p.e45-e53

2017

Volltextzugriff (PDF)

Outcome of patients with locally advanced breast cancer (LABC) followed at the University of Cincinnati (UC)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.21160-21160

2007

Volltextzugriff (PDF)

The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

BLOOD, 2018-11, Vol.132 (Supplement 1), p.1-1

2018

Volltextzugriff (PDF)

Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned

OncoTargets and therapy, 2016-08, Vol.2016 (Issue 1), p.4937-4957

2016

Volltextzugriff (PDF)

Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes

Journal of Blood Medicine, 2015-01, Vol.6 (default), p.1-16

2015

Volltextzugriff (PDF)

Treatment of unresectable or metastatic pancreatic cancer in the VA population: Does it improve survival?

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.15121-15121

2007

Volltextzugriff (PDF)

The myelodysplastic syndromes: Diagnosis, molecular biology and risk assessment

Hematology (Luxembourg), 2005-09, Vol.10 (sup1), p.258-269

2005

Volltextzugriff (PDF)

Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee

BLOOD, 2015-12, Vol.126 (23), p.907-907

2015

Volltextzugriff (PDF)

1 – 25 von 252

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(243)
Mit Volltextzugriff
(209)

Publikationsform

Sprache

Englisch
(252)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(92)
Science & Technology
(92)
Humans
(77)
Hematology
(74)
Oncology
(50)
Male
(41)
Female
(39)
Middle Aged
(38)
Aged
(36)
Adult
(29)
Myelodysplastic Syndromes
(28)
Mutation
(23)
Prognosis
(23)
Aged, 80 And Over
(21)
Hematology, Oncology And Palliative Medicine
(20)
Myelodysplastic Syndrome
(20)
Myelodysplastic Syndromes - Therapy
(20)
Myelodysplastic Syndromes - Diagnosis
(18)
Leukemia
(16)
Myelodysplastic Syndromes - Drug Therapy
(15)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Intrapatient functional clonality deconvoluted by coupling intracellular flow cytometry and next-generation sequencing in human leukemia

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS

Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia

An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies

P778: LONG‐TERM UTILIZATION AND BENEFIT OF LUSPATERCEPT IN PATIENTS (PTS) WITH LOWER‐RISK MYELODYSPLASTIC SYNDROMES (LR‐MDS) FROM THE MEDALIST TRIAL

P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE‐2 OR HIGH‐RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR

P995: MYELOID NEOPLASMS‐ASSOCIATED GENE VARIANTS IN 639 PATIENTS WITH POST‐POLYCYTHEMIA VERA AND POST‐ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT

Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes

An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms

Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes

The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure

Timing of allo-HCT in CMML

A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction

Outcome of Diffuse Large B-Cell Lymphoma in the United States Has Improved Over Time but Racial Disparities Remain: Review of SEER Data

Erratum: Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes

Between a Rux and a Hard Place: Investigating Causes of Ruxolitinib Discontinuation, Salvage Treatment and Outcome in Myelofibrosis

The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval

Outcome of patients with locally advanced breast cancer (LABC) followed at the University of Cincinnati (UC)

The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned

Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes

Treatment of unresectable or metastatic pancreatic cancer in the VA population: Does it improve survival?

The myelodysplastic syndromes: Diagnosis, molecular biology and risk assessment

Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee

Suchergebnisse filtern